AZ sells rights to statin med Crestor to Grünenthal
Grünenthal will pay $320m upfront for the rights
Read Moreby Lucy Parsons | Dec 1, 2020 | News | 0
Grünenthal will pay $320m upfront for the rights
Read Moreby Selina McKee | May 18, 2018 | News | 0
AstraZeneca’s first-quarter performance has taken a hit from generic competition to Crestor, but the firm says the results are no surprise and that it will swing back into the black this year.
Read Moreby Selina McKee | Apr 27, 2017 | News | 0
UK-based drug giants GlaxoSmithKline and AstraZeneca have reported a mixed bag of results for the first quarter of the year.
Read Moreby Selina McKee | Feb 2, 2017 | News | 0
AstraZeneca has booked a drop in revenues for the fourth quarter but says 2017 could be a ‘turning point’ for the firm as it comes to the end of its patent-expiry phase and begins its return to growth.
Read Moreby Selina McKee | Nov 10, 2016 | News | 0
AstraZeneca’s third-quarter net profit came in at 32 percent higher than a year ago, as a substantial one-time tax gain and currency exchange benefit helped weather falling sales during the period.
Read Moreby Selina McKee | Jul 11, 2016 | News | 0
AstraZeneca has filed a lawsuit to prevent the US Food and Drug Administration from approving the sale of generic versions of its multi-billion-dollar cholesterol drug Crestor.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
